The abstract is read at the publisher; the summary is JClub's.
High early on-treatment neutralizing anti-TILT-123 antibody titers (days 8–22) in 58 patients are linked to longer median OS (280 vs 190 days) and higher RECIST v1.1 response rates.
- Why it matters: Neutralizing antibodies can limit oncolytic adenovirus activity, but their kinetics, composition, and possible functional benefits as biomarkers or effectors in TILT-123 therapy remain unclear.
- What they did: Across three phase I trials, serum from 58 patients was tested for anti-TILT-123 nAbs with a cell-based functional neutralization assay, with ELISA for IgM/IgA/IgG and ADCP/ADCC functional assays.
- The result: Baseline anti-TILT-123 IgG and IgM correlated with prolonged OS, ADCP on day 36 associated with improved survival and disease control, and integrated profiling implicated lymphotoxin-α in early nAb induction.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.